Amorfix Life Sciences Ltd. Acquires SOD1 Technology and Provides Update on Financing
Published: Mar 12, 2012
TORONTO, March 12, 2012 /CNW/ - Amorfix Life Sciences Ltd. announces that it has exercised its option to acquire the SOD1 technology it had licensed from Chief Scientific Officer, Dr. Neil Cashman. The Company's SOD1 technology includes three issued patents and is currently sublicensed to Biogen Idec for the development of antibody therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and to Pan Provincial Vaccine Enterprise (PREVENT) for the development of vaccine applications. In addition, the Company is currently using this technology for the development of a diagnostic test for ALS.